RCKT Rocket Pharmaceuticals Inc

$RCKT Because there is 16 million short and 98% institutional ownership and 109 million outstanding shares retail may hold 5 million so where are they going to get the rest this will explode PERIOD. Plus we will get bought out shortly You don’t do a comprehensive company wide CIC for fun 🤩

$RCKT you do realize, management doesn't control the stock of the company right..... Its 95% institutionally owned, which means when the 1% decides they want it to run, they will make it run out of no where, no based on anything else. So you can be angry at everyone, but you are not yelling at the right plp. $RCKT is poised to run to $30-$50 and $90-$100 with BO, the science is there, the approvals are there, the lineup is there.... Only thing investors need is patience, why.... because the markets reward the patient, not the greedy who want everything NOW!, TODAY! Invest in the science and company. And learn to control the greed and ego.

$RCKT is further clarifying the FDA-aligned pivotal Phase 2 trial and reports that the first three patients treated with the modified dose have so far experienced no TMA or capillary leak syndrome, while all six key Phase 1 patients showed LAMP2 expression and at least a 10% reduction in LV mass after approximately 12 months. Also particularly interesting: reported short interest is around 15 million shares, roughly 17% of the float, with about 11 days to cover. If the market starts to reprice the safety risk, that could add a meaningful short squeeze component.

$RCKT Rocket Pharmaceuticals’ Danon update strengthens the RP-A501 story. The first 3 patients on the revised 3.8×10¹³ GC/kg dose completed the initial safety period without TMA or capillary leak syndrome. FDA has aligned on a 12-patient pivotal study, with ≥7 patients required to achieve BOTH LAMP2 expression and ≥10% LVMI reduction at 12 months. Three patients already count, leaving only 9 to dose, with completion targeted for mid-2027. Earlier Phase 1 data continue to show durable biological and cardiac effects, while Rocket sees a $1B+ peak opportunity in the initial male indication alone. The Hercules facility is another major positive: $35M upfront within a potential $150M facility, alongside $283.7M in existing cash/investments. Rocket expects funding into Q3 2028, with additional financing potentially extending runway into 2029 — reducing near-term dilution risk while funding the pivotal program and potential BLA. ::

$RCKT They are hunting it to bring it lower than $2, but just keep in mind that Total Cash Per Share (mrq) is $2.59. Silly season in biotechs...

The market is still pricing $RCKT as if there’s a meaningful chance RP-A501 never succeeds, the company’s valuation is roughly around its cash level, which means the Danon program is effectively being assigned very little value. That’s why tonight could be explosive!! if Rocket shows that the new dose is both safe and still biologically active, the market may have to sharply raise the probability of success, and reprice the entire stock accordingly. Anyone?

$RCKT I think this is an interesting stock leading up to the 10/06/2026 meeting. Elaborating on the FDA news could be a nice catalyst. 🚀🍌🦍

$RCKT is one I’m watching closely here. They already have an FDA-approved gene therapy, but the bigger catalyst could be Danon disease.

$RCKT honestly, i hate this market. Trump and his cronies are propping it up, spreading lies and diverting attention from every negative indicator to keep the market from collapsing. Still, this one looks like a bargain to me.

$RCKT this stock can not afford anymore good news. Nothing but good news has come out on this company since it received fda approval and it’s lost half its value since

$RCKT Rocket Pharmaceuticals, Inc. (RCKT) has entered into a credit facility agreement with Hercules Capital, Inc. (HTGC) for up to $150 million, according to a company press release.

$RCKT I was thinking the same…any updates on their participation at the Chardan’s 10th Annual Healthcare Conference? 🙏

$RCKT Danon update looks genuinely encouraging. Key takeaways from the RP-A501 event: • Pivotal success threshold: at least 7/12 patients achieving both LAMP2 ≥ Grade 1 and ≥10% LVMI reduction at 12 months. Phase I was 6/6 on these criteria. • First 3 patients at the recalibrated 3.8×10^13 GC/kg dose remain free of TMA/CLS, with follow-up now extending to ~3 months. • More patients are waiting than needed for the remaining 9 pivotal slots. Dosing completion remains guided for mid-2027. • Importantly, an earlier pivotal readout may be possible once the required number of responders is reached, rather than necessarily waiting for all 12 patients to complete 12 months. Management noted this possibility in the Q&A, although timing and the statistical approach still need to be finalized with the FDA. Overall: POSITIVE

$RCKT I think its a much cleaner path forward now that they have FDA alignment on the 12 patient pivotal Danon study, with the first three patients already counting toward that total

$RCKT I love the energy - however let me counter with why I dont believe that "Short Interest" is going anywhere.... Its going to be a LONG time before we get results - which means the RISK of something bad happening is LARGE..... we wont DERISK until results are released....

Cantor y'day reiterated Top Pick $RCKT Overweight-$15 after the Co. hosted a comprehensive update on RP-A501 (AAV9 gene-Tx) for Danon disease, providing add'l detail on the pivotal path, pt identification efforts, and the pot'l comm oppty. RGNX $TNYA $LXEO Cantor said in its note: Investors have had questions about both the safety profile of RP-A501 as well as the disease prevalence. With the recalibrated dose starting to show an acceptable safety profile and with today's update indicating robust progress identifying patients, the company is well on its way to addressing investors' concerns, as RCKT moves its way higher on our top picks list.

$RCKT from today's Danon Disease Program Update. Pretty much going to be waiting for Mid-2027 for dosing completion and then another year for the efficacy readout.

$RCKT Trading at cash value. So this is why Rckt is the perfect buyout target. It shouldn't take long. Sleep well, sleep tight. 💤 ❤️🌜🪐⭐️🌛❤️

$RCKT You are witnessing a Fall of epic proportions. Hide the women and children. Batten down the hatches. Head for the storm cellar. This is getting uglier than Maxine Waters' bare behind.

$RCKT I missed it, and now can’t find any information… did they give us an update on the effectiveness of the new dose?